Should you be buying the dip? Let's find out. CSL shares crashed 39% during 2025 to $172.65 as management slashed revenue and profit growth guidance, signalling that the biotherapeutics giant's next ...

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock. CSL shares fell nearly 40% in 2025 due to underwhelming profit guidance, elevated costs, ...

The College Swimming League (CSL), a revolutionary sports enterprise, today unveiled its plans to fundamentally reimagine college swimming. Founded by Robert Kent and Kyle Sockwell, with support from ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...

A rare 2023 BMW M4 CSL with only 1,600 miles is up for sale on Bring a Trailer. This lightweight, high-performance coupe looks almost new and demands attention. The Ultimate Driving Machine never ...

The exit delivers a 3.5x return CSL has grown around 20% annually ECI first invested in CSL in 2020 ECI Partners has exited CSL, a critical IoT connectivity business, into a continuation fund, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Australian biotechnology ...

Joy Linton, Chief Financial Officer of Australia's biotech company CSL talks about the company's restructuring, the impact of U.S. tariffs and currency volatility risks. Got a confidential news tip?

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine subsidiary in a wide-ranging restructure. The Melbourne-headquartered company will ...

SYDNEY—Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.

Aug 19 (Reuters) - Australian biotech giant CSL (CSL.AX), opens new tab said on Tuesday it plans to demerge its influenza vaccine division, CSL Seqirus, into a separately listed company by the end of ...